|Status: One Wales interim decision|
Using the agreed starting and stopping criteria, rituximab can be made available within NHS Wales for the second-line treatment of pemphigus (excluding pemphigus vulgaris) and fourth-line treatment of pemphigoid disease in adults and children whose disease has not responded to previous treatments including steroids and steroid-sparing agents.
The risks and benefits of the off-label use of rituximab for this indication should be clearly stated and discussed with the patient to allow informed consent.
In August 2017 OWMAG recommended this treatment in NHS Wales, in July 2023 there was a review of the recommendation. OWMAG found nothing new that effects the original decision.
Next review: this decision will be reviewed again after three years or earlier if new evidence becomes available.
|Formulation||Concentrate for solution for infusion|
Treatment of adults and children with pemphigus (excluding pemphigus vulgaris) after failure of first-line treatments, including steroids and steroid-sparing treatments, and after failure of third-line treatments for pemphigoid disease, including steroids and steroid-sparing treatments
|Submission type||One Wales|
|Status||One Wales interim decision|
|Date of issue||01/08/2017|
|Date of last review||July 2023|